Date	Price Target	Rating	Analyst
11/6/2024		Buy → Neutral	H.C. Wainwright
11/5/2024		Outperform → Sector Perform	RBC Capital Mkts
7/25/2023	$10.00	Hold → Buy	Needham
3/22/2023	$10.00	Buy	Jefferies
2/13/2023	$4.00 → $11.00	Sector Perform → Outperform	RBC Capital Mkts
5/25/2022	$16.00 → $4.00	Outperform → Sector Perform	RBC Capital Mkts
3/10/2022	$20.00	Buy	Brookline Capital
3/3/2022	$20.00 → $18.00	Buy	Needham

More analyst ratings

FDA Approval for YCANTH issued to VERRICA PHARMACEUTICALS INC

7/21/23 4:54:32 PM ET

$VRCA

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $VRCA alert in real time by email

New Drug Application (NDA): 212905
Company: VERRICA PHARMACEUTICALS INC

Products on NDA 212905

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
YCANTH	CANTHARIDIN	0.7%	SOLUTION;TOPICAL	Prescription	None	No	No

Approval Date(s) and History, Letters, Labels, Reviews for NDA 212905

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
07/21/2023	ORIG-1	Approval	Type 5 - New Formulation or New Manufacturer	PRIORITY		Label is not available on this site.

Get the next $VRCA alert in real time by email

Crush Q3 2025 with the Best AI Superconnector

Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

AI-Powered Inbox

Context-aware email replies

Strategic Decision Support

Get Started with Standout.work

Recent Analyst Ratings for
$VRCA

Date	Price Target	Rating	Analyst
11/6/2024		Buy → Neutral	H.C. Wainwright
11/5/2024		Outperform → Sector Perform	RBC Capital Mkts
7/25/2023	$10.00	Hold → Buy	Needham
3/22/2023	$10.00	Buy	Jefferies
2/13/2023	$4.00 → $11.00	Sector Perform → Outperform	RBC Capital Mkts
5/25/2022	$16.00 → $4.00	Outperform → Sector Perform	RBC Capital Mkts
3/10/2022	$20.00	Buy	Brookline Capital
3/3/2022	$20.00 → $18.00	Buy	Needham

More analyst ratings

$VRCA
Press Releases

Fastest customizable press release news feed in the world

View All

Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting

– Exploratory Phase 2 analysis shows Verrica's novel oncolytic peptide, VP-315, reprograms the tumor microenvironment, increasing cytotoxic T-cell infiltration and reducing immunosuppressive T-regulatory cells – – Findings provide mechanistic immunologic support for clinical efficacy previously reported, including 97% calculated objective response rate and 51% complete histologic clearance rate – – Coupled with VP-315's previously reported safety profile, these results highlight VP-315's potential as a first-in-class, non-surgical immunotherapeutic option for patients with basal cell carcinoma – WEST CHESTER, Pa., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica"

11/10/25 8:00:00 AM ET

$VRCA

Biotechnology: Pharmaceutical Preparations

Health Care

Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union

– EMA concludes that the primary endpoint and supportive secondary endpoints from prior successful Phase 3 studies conducted in the U.S. and Japan are adequate to support a filing for the approval of YCANTH® in the EU and that no additional Phase 3 studies are required – – Verrica is initiating activities to support this regulatory submission, which could be filed as early as Q4 2026 – WEST CHESTER, Pa., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ:VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that the Committee for Medicinal Products f

10/20/25 4:05:00 PM ET

$VRCA

Biotechnology: Pharmaceutical Preparations

Health Care

Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

WEST CHESTER, Pa., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that it will be presenting both an oral presentation and a poster on VP-315, its oncolytic peptide for the treatment of basal cell carcinoma (BCC), at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting taking place November 5–9, 2025, in National Harbor, Maryland. The abstract will be available on the SITC website on or about November 4, 2025, at 9 a.m. ET. Oral and Poster Presentation Details: Oral Presentation: Abstract Numbe

10/7/25 4:05:01 PM ET

$VRCA

Biotechnology: Pharmaceutical Preparations

Health Care

$VRCA
Financials

Live finance-specific insights

View All

Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025

WEST CHESTER, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Tuesday, August 12, 2025, to discuss the Company's financial results for the second quarter ending June 30, 2025, and provide a corporate update. Individuals may participate in the live call via telephone by dialing 1-800-267-6316 (domestic) or 1-203-518-9783 (international) and using the conference ID: VERRICA. Participants are asked to dial in 10 minutes before the star

8/6/25 7:00:00 AM ET

$VRCA

Biotechnology: Pharmaceutical Preparations

Health Care

Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025

WEST CHESTER, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Tuesday, May 13, 2025, to discuss the Company's financial results for the first quarter ending March 31, 2025, and provide a corporate update. Individuals may participate in the live call via telephone by dialing 1-800-343-4136 (domestic) or 1-203-518-9843 (international) and using the conference ID: VERRICA. Participants are asked to dial in 10 minutes before the start of

5/7/25 8:00:00 AM ET

$VRCA

Biotechnology: Pharmaceutical Preparations

Health Care

Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025

WEST CHESTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Tuesday, March 11, 2025, to discuss the Company's financial results for the fourth quarter and full year ending December 31, 2024, and provide a corporate update. Individuals may participate in the live call via telephone by dialing 1-800-445-7795 (domestic) or 1-785-424-1699 (international) and using the conference ID: VERRICA. Participants are asked to dial in 10 minut

3/3/25 7:00:00 AM ET

$VRCA

Biotechnology: Pharmaceutical Preparations

Health Care

$VRCA
Leadership Updates

Live Leadership Updates

View All

Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition

– Company reported $0 in product shipments in the third quarter of 2024 and recognized negative net product revenue of $1.9 million, including a provision for product returns of $1.7 million– – Company expects existing distributor inventory to support most demand for dispensed applicator units into the first quarter of 2025 – – Company continues to look for ways to manage expenses and expand access to YCANTH® for the treatment of molluscum contagiosum – – Company announces new senior leadership with appointments of Dr. Jayson Rieger as Chief Executive Officer and John Kirby as Interim Chi

11/4/24 4:05:00 PM ET

$VRCA

Biotechnology: Pharmaceutical Preparations

Health Care

Verrica Pharmaceuticals Reports Second Quarter 2021 Financial Results

WEST CHESTER, Pa., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the second quarter ended June 30, 2021. "This quarter, we continued to ramp up commercial preparations for the potential FDA approval of VP-102, our lead product candidate for the treatment of molluscum contagiosum, including strengthening our senior leadership team and ensuring patient access to VP-102 through productive dialogue with medical providers and payors," said Ted White, Verrica's President and Chief Executive Officer. "With a

8/10/21 7:30:00 AM ET

$VRCA

Biotechnology: Pharmaceutical Preparations

Health Care

Verrica Pharmaceuticals Announces Appointment of Terry Kohler as Chief Financial Officer

Company strengthens management team in anticipation of the potential commercial launch of VP-102, if approved WEST CHESTER, Pa., July 09, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the appointment of Terry Kohler as Chief Financial Officer. Mr. Kohler is a strategic and operational finance leader with over 20 years of commercial business experience, most recently at a global pharmaceutical company with annual revenues over $2 billion. Mr. Kohler is replacing Brian Davis, who is leaving Verrica to pursue other opportunities. "Te

7/9/21 7:30:00 AM ET

$VRCA

Biotechnology: Pharmaceutical Preparations

Health Care

FDA Approval for YCANTH issued to VERRICA PHARMACEUTICALS INC

Products on NDA 212905

Approval Date(s) and History, Letters, Labels, Reviews for NDA 212905

Original Approvals or Tentative Approvals

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for $VRCA

FDA Approval for YCANTH issued to VERRICA PHARMACEUTICALS INC

Products on NDA 212905

Approval Date(s) and History, Letters, Labels, Reviews for NDA 212905

Original Approvals or Tentative Approvals

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for $VRCA

$VRCA SEC Filings

Amendment: SEC Form SCHEDULE 13G/A filed by Verrica Pharmaceuticals Inc.

SEC Form 10-Q filed by Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

$VRCA Press Releases

Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting

Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union

Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

$VRCA Insider Purchases

Director Stalfort John A Iii bought 1,123,595 shares and received a gift of 50,000 shares, increasing direct ownership by 168% to 1,873,800 units (SEC Form 4)

CEO and President Rieger Jayson bought 280,898 shares and received a gift of 50,000 shares, increasing direct ownership by 60% to 882,826 units (SEC Form 4)

Director Manning Paul B bought 22,921,348 shares and gifted 450,000 shares (SEC Form 4)

$VRCA Insider Trading

SEC Form 4 filed by Director Nguyen Diem

SEC Form 4 filed by Director Corcoran Gavin

SEC Form 4 filed by Director Prygocki Mark A Sr

$VRCA Analyst Ratings

Verrica Pharmaceuticals downgraded by H.C. Wainwright

Verrica Pharmaceuticals downgraded by RBC Capital Mkts

Verrica Pharmaceuticals upgraded by Needham with a new price target

$VRCA FDA approvals